SCHEMBL622376

SCHEMBL622376

COc1ccc2ccc(Cl)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
GFER P55789 1/20 0.56
KDM4E B2RXH2 4/20 0.54
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
NQO2 P16083 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NCF1 P14598 1/20 0.50
EGFR P00533 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP2A6 P11509 1/20 0.47
HPGDS O60760 2/20 0.44
NQO1 P15559 1/20 0.43
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483893 0.86 NCF1 (0.68) ALDH1A1GFERKDM4EKMT2ANPC1
Hydrochloric Acid SCHEMBL27511022 0.85 NCF1 (0.66) ALDH1A1GFERKDM4EKMT2ANPC1
SCHEMBL11343519 0.80 NCF1 (0.76) ALDH1A1GFERKDM4EKMT2ANPC1
SCHEMBL17430096 0.79 FGFR1 (0.41) ALDH1A1GFERKDM4EKMT2AL3MBTL1
SCHEMBL2320403 0.79 NCF1 (0.53) ALDH1A1KDM4EKMT2ANPC1RAB9A
SCHEMBL20909590 0.78 NCF1 (0.49) ALDH1A1GFERKDM4ENCF1CYP1A2
SCHEMBL7231065 0.78 CCR1 (0.53) ALDH1A1GFERNPC1RAB9ACYP1A2
SCHEMBL424930 0.78 CYP1A2 (0.57) ALDH1A1GFERKDM4EKMT2ANPC1
SCHEMBL30081480 0.78 CYP1A2 (0.57) ALDH1A1GFERKDM4EKMT2ANPC1
SCHEMBL12068392 0.77 ALDH1A1 (0.57) ALDH1A1GFERKDM4EKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106854180-A A kind of preparation method of the acid amides of 4 chlorine, 7 methoxy quinoline 6 山东轩德医药科技有限公司 2017-06-16 CN claimed
CN-105037266-A Antibacterial chloroxoquinoline derivative WANG ZIHOU 2015-11-11 CN claimed
CN-105017145-A Chloroxoquinoline derivative with anti-tumor activity WANG ZIHOU 2015-11-04 CN claimed
CN-104918941-A Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2015-09-16 CN claimed
CN-104876864-A Preparation method of lenvatinib BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEV CO LTD 2015-09-02 CN claimed
CN-103864681-A Chloroxoquinoline derivatives for antibacterial use WANG ZIHOU 2014-06-18 CN claimed
CN-103864680-A Chloroxoquinoline derivative with antineoplastic activity WANG ZIHOU 2014-06-18 CN claimed
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 US disclosed
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 US disclosed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 EP disclosed
CN-119403554-A Therapeutic or prophylactic agent for amyotrophic lateral sclerosis 东丽株式会社 2025-02-07 CN disclosed
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2024-04-11 US disclosed
CN-103797024-A Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2014-05-14 CN disclosed
US-8716280-B2 Bicyclic antibiotics BASILEA PHARMACEUTICA AG (CH) 2014-05-06 US disclosed
CN-103420986-A Substituted quinoline compounds, methods of use, and uses thereof GUANGDONG HEC PHARMACEUTICAL 2013-12-04 CN disclosed
US-20120040957-A1 Novel Bicyclic Antibiotics BASILEA PHARMACEUTICA AG 2012-02-16 US disclosed
EP-2389376-A1 NOVEL BICYCLIC ANTIBIOTICS Basilea Pharmaceutica AG (CH) 2011-11-30 EP disclosed
WO-2010084152-A1 NOVEL BICYCLIC ANTIBIOTICS BASILEA PHARMACEUTICA AG (CH) 2010-07-29 WO disclosed
CN-1478078-A Nitrogen-containing aromatic ring derivatives ������������ʽ���� 2004-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF AIFM2, TXNRD2, NFE2L2 ALDH1A1 2714/4885GFER 1685/4885KDM4E 2935/4885
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 ALDH1A1 2086/4885GFER 143/4885KDM4E 2176/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 ALDH1A1 3280/4885GFER 794/4885KDM4E 1759/4885
US-20120040957-A1 Novel Bicyclic Antibiotics C5, C1S, CBR3 ALDH1A1 4235/4885GFER 1311/4885KDM4E 3573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.